IntroductionThe cutaneous polymorphic eruption of pregnancy (PEP) is presented by skin lesions usually in the third trimester of gestation and about 13% of women also suffer from perinatal depression.ObjectiveTo determine the frequency of pruritic urticarial papules of gestation with and without perinatal depression.AimTo assess the maternal causes for polymorphic eruption of pregnancy (PEP) in patients with and without perinatal depression.MethodsCases and controls were matched on the grounds of maternal weight gain in gestation, hormonal changes, deficit in iron and zinc, dysregulation of hypothalamic pituitary axis, pre-maturity, pre-eclampsia, pre-term labour. Univariate and multivariate analysis, adjusting for important demographic factors and comorbodities was conducted to assess the relationship of PEP with and without perinatal depression in reduced and full models of ANOVA in regression analysis. (Reduced model Y = β0 + β1X1 + … and the full model Y = β0 + β1X1 + β2X2 + β3X3 + β4X4 + β5X5 + β6X6 + …)ResultsPolymorphic eruption of pregnancy with perinatal depression was statistically significant in maternal weight gain in gestation [odds ratio (OR) 1.20; 95% (CI): 1.15–1.30], hormonal changes [(OR) 2.78; 95% (CI): 2.52–2.82], deficit in iron and zinc [(OR) 2.18; 95% (CI): 2.04–2.38], dysregulation of hypothalamic pituitary axis [(OR) 1.37; 95% (CI): 1.18–1.49] and was not statistically significant in pre-maturity, pre-eclampsia and pre-term labour in cases and controls.ConclusionPruritic urticarial papules and plaques of gestation are commonly associated in patients with perinatal derpession.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Background: HSP is typically a disease of children between the ages of 3 and 10 years. Although adult cases have been described, 50% of all cases occur at or before the age of 5 years. Males are affected twice as often as females. In North America, Caucasians have the highest prevalence, and African Americans have the lowest prevalence. Although the cause of HSP is unknown, it commonly follows an upper respiratory tract infection. As a result, the disease is more common in winters. Objectives: To determine the prevalence of Henoch-Schonlein purpura (HSP) in children. To determine the seasonal variation of Henoch-Schonlein purpura (HSP) in children. Materials and Methods: This was a cross sectional study conducted at Jinnah Postgraduate Medical Center & Karachi Medical & Dental College. Children (<17 yr of age) diagnosed with HSP were included on the basis of non-probability convenient sampling. The diagnosis of HSP was based on the standard defined by the American College of Rheumatology. The sample size calculation was done using the World Health Organization, Geneva software where α=5%, 1-Beta=80, Po=0.15, Pa=0.20, sample size=342. Continuous variables like age and number of patients admitted at various time of year were presented as mean ± standard deviation. Categorical variables, gender and age (<14, >14 years) were presented as proportions. Results: Mean age of children with HSP was 11 ± 1.5 years. Majority of the children 43.6% were <14 years of age in 2017 and 51.2% in 2018. The annual prevalence of HSP from 2017 till 2018 increased to 9.2%. The frequency of hospitalization also increased, 2017: 40%; 2018: 59%. Males were 71% and females were 28%. Male to female ratio was 2.0. Males >10 years were 29% and females >10 years were 70% (p<0.05) Table1. Number of cases increased from 8-12 years of age and were less frequent in <8 years and >14 years of age. Majority, 20% of cases were of 10 years age. HSP occur all year round with a high prevalence in the winter season. Number of patients increased from 2% in June and July to 58% from November till February. Conclusion: The overall prevalence of HSP was 19.5 per 1000 affecting children of 9 to 11 years in winters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.